Wk 6-8) Pharmacology of Thrombolytic Drugs: Mechanism of Action, Indications, and Adverse Effects

Overview of Thrombolytic Drugs

• Thrombolytic drugs, also colloquially known as "clot-busting drugs," are pharmaceutical agents designed to actively lyse or break down existing thrombi (blood clots).

• These drugs differ from anticoagulants (which stop the coagulation cascade) and antiplatelets (which stop platelet aggregation) because they address clots that have already formed in the vasculature.

• The primary goal of this session is to understand the mechanism of action (MOA) and the adverse effects associated with these thrombolytic agents.

Physiology of Fibrin Formation and Degradation

• Fibrinogen and Thrombin:

  • Fibrinogen is a soluble peptide present in the blood.

  • The enzyme thrombin cleaves fibrinogen to convert it into fibrin.

  • Glycoprotein IIb/IIIa ($GP\,IIb/IIIa$) is the protein complex that binds to fibrinogen to facilitate platelet bridging.

• Fibrin Characteristics:

  • Fibrin is an insoluble polypeptide.

  • It forms a gel-like substance, creating the structural framework of a thrombus. In a clinical or laboratory setting, this appears as a jelly-like red mass that can be easily extracted from a vessel or tube.

• Fibrinolysis (The Breakdown Process):

  • In the body, fibrinolysis is a natural regulatory process that prevents uncontrolled coagulation and platelet aggregation.

  • Plasminogen: This is an inactive precursor or "zymogen" protein.

  • Tissue Plasminogen Activator (tPA): This is the key enzyme that cleaves or activates plasminogen to transform it into its active form, plasmin.

  • Plasmin: Plasmin acts as a proteolytic enzyme that cuts the insoluble fibrin strands into smaller, soluble fragments known as fibrin degradation products.

  • Once fibrin is broken down into these products, the thrombus becomes solubilized and dissolves.

Mechanism of Action of Thrombolytics

• Serine Proteases:

  • Tissue plasminogen activators (tPA) are classified as serine proteases.

  • They are named "serine proteases" because they selectively cleave protein chains at the serine amino acid residues.

• Pharmacodynamic Action:

  • The drug (tPA) mimics the endogenous process by cleaving plasminogen to produce plasmin.

  • The resulting plasmin then degrades the fibrin meshwork within the clot, effectively breaking the "glue" that holds the thrombus together.

• Recombinant Technology:

  • Modern medicine utilizes recombinant DNA technology to produce these activators (r-tPA).

  • By understanding the human gene for tPA, scientists can bioengineer drugs with specific modifications to reach different clinical goals.

Specific Thrombolytic Agents

• Alteplase:

  • Alteplase has a short half-life.

  • It is used in scenarios where a rapid, high-intensity action is required (a "get in, chew up the clot, and get out" approach).

• Tenecteplase:

  • Tenecteplase is a modified form of tPA designed to have a longer half-life.

  • This allows for a more sustained effect or may be administered at lower doses depending on the clinical requirement for stability in the bloodstream.

Clinical Indications for Thrombolytic Use

• Myocardial Infarction (MI): Used to dissolve clots in coronary vessels to restore blood flow to the heart muscle.

• Venous Thromboembolism (VTE) and Deep Vein Thrombosis (DVT): These drugs can be used to break down clots such as those found in "Mary's leg" (an example of a DVT scenario).

• Arterial Thromboembolism: Treatment for clots located in systemic or coronary arteries.

• Acute Ischemic Stroke:

  • Occurs when a thrombus travels to and blocks cerebral vessels, cutting off blood supply to a portion of the brain.

  • Thrombolytics are "clot busters" that can break these blockages.

  • Critical Timing: If administered early enough, the drug can restore blood supply and save the affected brain region from permanent damage during an ischemic event.

• Contraindicated in Hemorrhagic Stroke:

  • It is vital to distinguish between stroke types. Hemorrhagic stroke involves a burst blood vessel and active bleeding into the brain.

  • Thrombolytics are strictly not for use in hemorrhagic stroke, as they would exacerbate the bleeding; they are only indicated for ischemic stroke (blockage).

Adverse Effects and Safety

• Bleeding: The primary and most significant adverse effect of tissue plasminogen activators is bleeding.

• Because these drugs systematically "chew up" fibrin and break down thrombi, they can interfere with the body's ability to maintain necessary clots at sites of vascular repair, leading to potentially dangerous hemorrhaging.